Keytruda's dominance as a mainstay in cancer immunotherapy isn’t threatened by an experimental Chinese drug, a top Merck ...

Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024 ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

An academic partnership to improve diversity in clinical trials has drafted its first industry team members. | An academic ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

One year after reporting a split result on Merck’s Welireg in a key phase 3 trial, the song remains the same for the kidney ...

Rahway: Merck, known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., ...

So we're in a private market in India, and we work with and it was a Tata Medical Center in Mumbai. And we work very closely with them and the other two third parties to ensure that if a patient needs ...